Exabis Library
Welcome to the e-CCO Library!
P366: Escherichia coli Nissle 1917 in ulcerative colitis treatment: systematic review and meta-analysis
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P366: Exclusive enteral nutrition drives protective microbiome modulation in paediatric Crohn's Disease
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P366: genomics analysis and differentiation of Crohn's Disease, Intestinal Tuberculosis and Primary Intestinal Iymphoma
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P366: Long-term evolution of gastrointestinal immune-related adverse events (GI-IrAE) induced by immune checkpoint inhibitors (ICI)
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P366: The efficacy of vedolizumab for induction of clinical response and remission in anti-TNF naïve patients with inflammatory bowel disease – a multicenter European real world experience
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P366: Vedolizumab maintenance therapy reduced use of corticosteroids in patients with Crohn’s disease in the GEMINI 2 trial
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P367 Real-life long-term effectiveness and treatment persistence of vedolizumab in a single tertiary care cohort of Crohn’s disease patients
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P367: Lower quality of life, more active disease and increased healthcare costs due to non-adherence in inflammatory bowel disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P367: Nutrition advice for IBD patients as a useful complementary strategy: a single-centre cohort intervention
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P367: quality of life in patients with Inflammatory Bowel Disease
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P367: Significant impact on health care utilization upon implementation of an electronic IBD care management program.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P367: The availability of infliximab trough levels in IBD patients on maintenance therapy deeply impacts therapeutic decision-making
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P367: Vedolizumab and early postoperative complications in non-intestinal surgery: A case-matched analysis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P367: Weight patterns in biologicals treated Inflammatory bowel disease cohort
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P368 Tofacitinib induction efficiency and intracellular cytokine dynamics in ulcerative colitis: Results from clinical practice
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P368: Persistence of biologic therapy and mapping of sequential biologic use: Results of a single centre cohort with 841 patients treated over 18 years
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P368: Proactive Therapeutic Drug Monitoring is more effective than Conventional Management in Inducing Fecal Calprotectin remission in Inflammatory Bowel Disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P368: Risk factors for serious infections in elderly patients receiving infliximab and other Crohn’s disease therapies: TREAT™ registry data
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P368: Safety issues of azathioprine in patients with inflammatory bowel disease: clinical experience from a referral center
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P368: The presence of extra-intestinal manifestations is associated with poor prognosis in acute severe ulcerative colitis: A KASID multicenter study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM